1-(4-bromophenyl)-2-phenylethan-1-one, also known as **4-bromo-α-phenylacetophenone**, is an organic compound with a structure that consists of:
* **A phenyl group (C6H5) attached to a ketone (C=O) group.**
* **A second phenyl group attached to the carbon adjacent to the ketone.**
* **A bromine atom at the para position (position 4) of the first phenyl ring.**
This specific structure makes it interesting for research due to its potential applications:
**1. Building Block for Pharmaceuticals and Agrochemicals:**
* **Versatile synthetic intermediate:** The compound can serve as a starting material for synthesizing a range of other molecules with diverse biological activities.
* **Lead compound optimization:** It can be modified by introducing different functional groups to explore structure-activity relationships and develop more potent drugs or agrochemicals.
**2. Biological Activity:**
* **Potential anti-inflammatory properties:** Preliminary research suggests this compound might exhibit anti-inflammatory effects, possibly due to its ability to inhibit the production of inflammatory mediators.
* **Other potential applications:** Research is ongoing to investigate its potential activity against cancer, bacteria, and fungi.
**3. Synthetic Chemistry:**
* **Reactivity:** The bromine atom provides a convenient handle for further functionalization via nucleophilic aromatic substitution reactions.
* **Study of reaction mechanisms:** This compound can serve as a model system for understanding the reaction mechanisms involved in different synthetic transformations.
**4. Material Science:**
* **Polymeric materials:** The compound could be used in the synthesis of polymers with unique optical or electronic properties.
**It's important to note that:**
* While research is promising, 1-(4-bromophenyl)-2-phenylethan-1-one is still in early stages of development. More extensive research is needed to fully understand its properties and potential applications.
* **Safety information:** As with any chemical, it's crucial to handle this compound with caution and proper safety procedures.
Overall, 1-(4-bromophenyl)-2-phenylethan-1-one represents a valuable research tool with potential for application in various fields. It provides a starting point for further exploration and development of new materials, drugs, and technologies.
ID Source | ID |
---|---|
PubMed CID | 519738 |
CHEBI ID | 190542 |
SCHEMBL ID | 1351697 |
Synonym |
---|
4-bromodesoxybenzoin |
benzyl 4-bromophenyl ketone |
AH-034/01393018 |
1-(4-bromophenyl)-2-phenylethanone , |
benzyl 4-bromophenyl ketone, 97% |
MAYBRIDGE4_003239 |
NCGC00176058-01 |
HMS1530D05 |
2001-29-8 |
b2020 , |
BRD-K64462698-001-01-5 |
STL011094 |
1-(4-bromophenyl)-2-phenylethan-1-one |
CHEBI:190542 |
4'-bromo-2-phenylacetophenone |
benzylbromanuidyl(phenyl)methanone |
A814165 |
AKOS005202967 |
ethanone,1-(4-bromophenyl)-2-phenyl- |
FT-0622765 |
AB01330624-02 |
BBL027816 |
4--bromodeoxybenzoin |
4-bromodeoxybenzoin |
1-(4-bromo-phenyl)-2-phenyl-ethanone |
2-phenyl-p-bromoacetophenone |
SCHEMBL1351697 |
ethanone, 1-(4-bromophenyl)-2-phenyl- |
AC-30019 |
1-(4-bromophenyl)-2-phenylethanone # |
mfcd00016331 |
DTXSID10334126 |
J-012941 |
NCGC00176058-02 |
DS-6553 |
benzyl 4-brornophenyl ketone |
D70861 |
4 inverted exclamation mark -bromo-2-phenylacetophenone |
SY049175 |
AB90876 |
CS-0156335 |
?4'-bromo-2-phenylacetophenone |
phenyl-(phenylmethyl)bromanuidylmethanone |
Class | Description |
---|---|
stilbenoid | Any olefinic compound characterised by a 1,2-diphenylethylene backbone. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.13) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |